These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954 [TBL] [Abstract][Full Text] [Related]
3. Delivery of Tong Z; Zhang X; Guo X; Wu G; Cao S; Zhang Y; Meng X; Wang T; Wang Y; Song Y; Yang R; Du Z mSphere; 2024 Sep; 9(9):e0033024. PubMed ID: 39158304 [TBL] [Abstract][Full Text] [Related]
4. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague. Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643 [TBL] [Abstract][Full Text] [Related]
5. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague. Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353 [TBL] [Abstract][Full Text] [Related]
7. Complete Protection Against Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W Front Immunol; 2022; 13():793382. PubMed ID: 35154110 [TBL] [Abstract][Full Text] [Related]
8. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague. Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB mBio; 2018 Oct; 9(5):. PubMed ID: 30327445 [No Abstract] [Full Text] [Related]
9. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Yamanaka H; Hoyt T; Yang X; Golden S; Bosio CM; Crist K; Becker T; Maddaloni M; Pascual DW Infect Immun; 2008 Oct; 76(10):4564-73. PubMed ID: 18694965 [TBL] [Abstract][Full Text] [Related]
10. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination. Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734 [TBL] [Abstract][Full Text] [Related]
11. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague. Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342 [TBL] [Abstract][Full Text] [Related]
12. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834 [TBL] [Abstract][Full Text] [Related]
13. Sex differences in immune protection in mice conferred by heterologous vaccines for pneumonic plague. Davies ML; Biryukov SS; Rill NO; Klimko CP; Hunter M; Dankmeyer JL; Miller JA; Shoe JL; Mlynek KD; Talyansky Y; Toothman RG; Qiu J; Bozue JA; Cote CK Front Immunol; 2024; 15():1397579. PubMed ID: 38835755 [TBL] [Abstract][Full Text] [Related]
14. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague. Levy Y; Flashner Y; Tidhar A; Zauberman A; Aftalion M; Lazar S; Gur D; Shafferman A; Mamroud E Vaccine; 2011 Sep; 29(40):6866-73. PubMed ID: 21803090 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine. Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803 [TBL] [Abstract][Full Text] [Related]
16. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652 [TBL] [Abstract][Full Text] [Related]
17. Plague vaccines and the molecular basis of immunity against Yersinia pestis. Quenee LE; Schneewind O Hum Vaccin; 2009 Dec; 5(12):817-23. PubMed ID: 19786842 [TBL] [Abstract][Full Text] [Related]
18. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Huang J; D'Souza AJ; Alarcon JB; Mikszta JA; Ford BM; Ferriter MS; Evans M; Stewart T; Amemiya K; Ulrich RG; Sullivan VJ Clin Vaccine Immunol; 2009 May; 16(5):719-25. PubMed ID: 19261773 [TBL] [Abstract][Full Text] [Related]
19. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. Chichester JA; Musiychuk K; Farrance CE; Mett V; Lyons J; Mett V; Yusibov V Vaccine; 2009 May; 27(25-26):3471-4. PubMed ID: 19200825 [TBL] [Abstract][Full Text] [Related]
20. A single dose sub-unit vaccine protects against pneumonic plague. Williamson ED; Eley SM; Stagg AJ; Green M; Russell P; Titball RW Vaccine; 2000 Oct; 19(4-5):566-71. PubMed ID: 11027822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]